Hyperfine (HYPR) Non-Current Debt (2020 - 2026)

Hyperfine (HYPR) posted Non-Current Debt of $13.1 million for Q1 2026, up 7272.47% on a QoQ basis from $178000.0 in Q4 2020.

Hyperfine (HYPR) Non-Current Debt (2020 - 2026) Analysis & Trends

Hyperfine's Non-Current Debt history runs 2 years deep, the most recent figure standing at $13.1 million for Q1 2026.

  • Quarterly Non-Current Debt changed N/A year-over-year to $13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.1 million (changed N/A YoY) and the FY2020 annual result came in at $178000.0, changed N/A from the prior year.
  • Non-Current Debt was $13.1 million for Q1 2026 at Hyperfine, up from $178000.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $13.1 million in Q1 2026 and bottomed at $13.1 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 29.64 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 14.22 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 26.17 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 10.99 Bn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn 598.50 Mn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn -
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 8.07 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 10.13 Bn
9 Smith & Nephew 25.80 Bn 25.22 Bn - 3.18 Bn
10 Hyperfine 92.81 Mn 51.53 Mn 1.98 Mn 13.12 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 13.12 Mn
Dec 31, 2020 178,000.00